Limits...
CtBP2 overexpression is associated with tumorigenesis and poor clinical outcome of prostate cancer.

Zhang C, Li S, Qiao B, Yang K, Liu R, Ma B, Liu Y, Zhang Z, Xu Y - Arch Med Sci (2015)

Bottom Line: CtBP2 overexpression was closely correlated with serum prostatic specific antigen (PSA) (p = 0.018), advanced tumor stage (T3) (p = 0.025), higher Gleason scores (p = 0.019), positive extraprostatic extension (p = 0.012), positive vascular invasion (p = 0.011) and perineural invasion (p = 0.035).However, no significant association was found between CtBP2 abnormal expression and other parameters, including age (p = 0.776), positive lymph node (p = 0.872) and positive surgical margin (p = 0.37).Moreover, CtBP2 overexpression was significantly associated with poor clinical outcome of prostate cancer (p = 0.0168).

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.

ABSTRACT

Introduction: The aim of the study was to evaluate the expression of CtBP2 in prostate cancer and to determine its relationship with clinicopathologic parameters.

Material and methods: The expression of CtBP2 in 119 prostate cancer tissues and 41 normal tissues was examined by qPCR and Western blot analysis, and the results were correlated with clinicopathologic parameters.

Results: CtBP2 expression in prostate cancer tissues was higher than that in normal samples. CtBP2 overexpression was closely correlated with serum prostatic specific antigen (PSA) (p = 0.018), advanced tumor stage (T3) (p = 0.025), higher Gleason scores (p = 0.019), positive extraprostatic extension (p = 0.012), positive vascular invasion (p = 0.011) and perineural invasion (p = 0.035). However, no significant association was found between CtBP2 abnormal expression and other parameters, including age (p = 0.776), positive lymph node (p = 0.872) and positive surgical margin (p = 0.37). Moreover, CtBP2 overexpression was significantly associated with poor clinical outcome of prostate cancer (p = 0.0168).

Conclusions: CtBP2 is overexpressed in prostate cancer, and its increased expression is closely associated with tumor progression and the outcome of prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Increased expression of CtBP2 in prostate cancers. A – The relative mRNA expression of CtBP2 was assessed by qRT-PCR analysis in prostate cancer tissues compared to normal samples (p = 0.0012). B – Representative images of the CtBP2 protein level from different specimens, evaluated by Western blot analysis. The quantified data for CtBP2 were normalized to GAPDH. C – Kaplan-Meier survival curves displayed the relationship between CtBP2 mRNA expression and survival of prostate cancer patients. An appropriate cutoff of CtBP2 abnormal expression was applied, above which it was considered as overexpressed and below as low-expressed, and the mean level was used
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4697064&req=5

Figure 0001: Increased expression of CtBP2 in prostate cancers. A – The relative mRNA expression of CtBP2 was assessed by qRT-PCR analysis in prostate cancer tissues compared to normal samples (p = 0.0012). B – Representative images of the CtBP2 protein level from different specimens, evaluated by Western blot analysis. The quantified data for CtBP2 were normalized to GAPDH. C – Kaplan-Meier survival curves displayed the relationship between CtBP2 mRNA expression and survival of prostate cancer patients. An appropriate cutoff of CtBP2 abnormal expression was applied, above which it was considered as overexpressed and below as low-expressed, and the mean level was used

Mentions: In order to assess the biogenic role of CtBP2 in prostate cancers, we examined the expression of CtBP2 in tumor and normal tissues by RT-qPCR and Western blot analysis. The results showed that the mRNA level of CtBP2 was increased 2-fold in tumor tissues compared to normal tissues (Figure 1 A, p = 0.012), and a similar result was also observed in the protein level (Figure 1 B), consist with previous study [10], suggesting that CtBP2 upregulation might be closely involved in the tumorigenesis and tumor progression of prostate cancer.


CtBP2 overexpression is associated with tumorigenesis and poor clinical outcome of prostate cancer.

Zhang C, Li S, Qiao B, Yang K, Liu R, Ma B, Liu Y, Zhang Z, Xu Y - Arch Med Sci (2015)

Increased expression of CtBP2 in prostate cancers. A – The relative mRNA expression of CtBP2 was assessed by qRT-PCR analysis in prostate cancer tissues compared to normal samples (p = 0.0012). B – Representative images of the CtBP2 protein level from different specimens, evaluated by Western blot analysis. The quantified data for CtBP2 were normalized to GAPDH. C – Kaplan-Meier survival curves displayed the relationship between CtBP2 mRNA expression and survival of prostate cancer patients. An appropriate cutoff of CtBP2 abnormal expression was applied, above which it was considered as overexpressed and below as low-expressed, and the mean level was used
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4697064&req=5

Figure 0001: Increased expression of CtBP2 in prostate cancers. A – The relative mRNA expression of CtBP2 was assessed by qRT-PCR analysis in prostate cancer tissues compared to normal samples (p = 0.0012). B – Representative images of the CtBP2 protein level from different specimens, evaluated by Western blot analysis. The quantified data for CtBP2 were normalized to GAPDH. C – Kaplan-Meier survival curves displayed the relationship between CtBP2 mRNA expression and survival of prostate cancer patients. An appropriate cutoff of CtBP2 abnormal expression was applied, above which it was considered as overexpressed and below as low-expressed, and the mean level was used
Mentions: In order to assess the biogenic role of CtBP2 in prostate cancers, we examined the expression of CtBP2 in tumor and normal tissues by RT-qPCR and Western blot analysis. The results showed that the mRNA level of CtBP2 was increased 2-fold in tumor tissues compared to normal tissues (Figure 1 A, p = 0.012), and a similar result was also observed in the protein level (Figure 1 B), consist with previous study [10], suggesting that CtBP2 upregulation might be closely involved in the tumorigenesis and tumor progression of prostate cancer.

Bottom Line: CtBP2 overexpression was closely correlated with serum prostatic specific antigen (PSA) (p = 0.018), advanced tumor stage (T3) (p = 0.025), higher Gleason scores (p = 0.019), positive extraprostatic extension (p = 0.012), positive vascular invasion (p = 0.011) and perineural invasion (p = 0.035).However, no significant association was found between CtBP2 abnormal expression and other parameters, including age (p = 0.776), positive lymph node (p = 0.872) and positive surgical margin (p = 0.37).Moreover, CtBP2 overexpression was significantly associated with poor clinical outcome of prostate cancer (p = 0.0168).

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China.

ABSTRACT

Introduction: The aim of the study was to evaluate the expression of CtBP2 in prostate cancer and to determine its relationship with clinicopathologic parameters.

Material and methods: The expression of CtBP2 in 119 prostate cancer tissues and 41 normal tissues was examined by qPCR and Western blot analysis, and the results were correlated with clinicopathologic parameters.

Results: CtBP2 expression in prostate cancer tissues was higher than that in normal samples. CtBP2 overexpression was closely correlated with serum prostatic specific antigen (PSA) (p = 0.018), advanced tumor stage (T3) (p = 0.025), higher Gleason scores (p = 0.019), positive extraprostatic extension (p = 0.012), positive vascular invasion (p = 0.011) and perineural invasion (p = 0.035). However, no significant association was found between CtBP2 abnormal expression and other parameters, including age (p = 0.776), positive lymph node (p = 0.872) and positive surgical margin (p = 0.37). Moreover, CtBP2 overexpression was significantly associated with poor clinical outcome of prostate cancer (p = 0.0168).

Conclusions: CtBP2 is overexpressed in prostate cancer, and its increased expression is closely associated with tumor progression and the outcome of prostate cancer.

No MeSH data available.


Related in: MedlinePlus